MetaADEDB 2.0 @ LMMD
cetrorelix
(SBNPWPIBESPSIF-MHWMIDJBSA-N)
Structure
SMILES
OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCN=C(N)N)CC(C)C)CCCNC(=O)N)Cc1ccc(cc1)O)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(cc1)Cl)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C
Type(s)
Approved; Investigational
ATC code(s)
H01CC02
Molecular Formula:
C70H92ClN17O14
Molecular Weight:
1431.040
Log P:
5.9323
Hydrogen Bond Acceptor:
31
Hydrogen Bond Donor:
16
TPSA:
498.17
CAS Number(s):
120287-85-6; 130143-01-0
Synonym(s)
1.
cetrorelix
2.
Cetrotide
3.
LHRH, N-Ac-1-Nal(2)-2-Phe(pCl)-3-Pal(3)-6-Cit-10-Ala-
4.
LHRH, N-acetyl-1-(3-(2-naphthyl)alanyl)-2-(4-chlorophenylalanyl)-3-(3-(3-pyridyl)alanyl)-6-citrulline-10-alanine-
5.
N-acetyl-1-(3-(2-naphthyl)alanine)-2-(4-chlorophenylalanine)-3-(3-(3-pyridyl)alanine)-6-citrulline-10-alanine-LHRH
6.
SB 75
7.
SB-75
8.
cetrorelix acetate
9.
cetrorelix pamoate
External Link(s)
MeSHC062876
PubChem Compound25074887
BindingDB50369965
ChEBI59224
CHEMBLCHEMBL1200490
DrugBankDB00050
DrugCentral583
IUPHAR/BPS Guide to PHARMACOLOGY1190
KEGGdr:D01685
dr:D07665
Therapeutic Target DatabaseD09OLZ
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 7
Canada Vigilance: 4		Canada Vigilance
US FAERS
2Injection site urticariaFAERS: 7US FAERS
3PruritusFAERS: 7SIDER
US FAERS
4Premature ovulationFAERS: 5US FAERS
5Unevaluable eventFAERS: 5US FAERS
6UrticariaFAERS: 5US FAERS
7DizzinessFAERS: 4US FAERS
8NauseaFAERS: 4SIDER
US FAERS
9Drug exposure during pregnancyFAERS: 3US FAERS
10Feeling abnormalFAERS: 3US FAERS
11HeadacheFAERS: 3SIDER
US FAERS
12Injury associated with deviceFAERS: 3US FAERS
13Peritoneal fluid analysis abnormalFAERS: 3US FAERS
14AstheniaFAERS: 2US FAERS
15Chest discomfortFAERS: 2US FAERS
16Cold sweatFAERS: 2US FAERS
17Ectopic PregnancyFAERS: 2US FAERS
18ErythemaFAERS: 2SIDER
US FAERS
19HypersensitivityFAERS: 2SIDER
US FAERS
20Injection site erythemaFAERS: 2US FAERS
21Injection site pruritusFAERS: 2US FAERS
22NecrosisFAERS: 2US FAERS
23Needle issueFAERS: 2US FAERS
24Ovarian Hyperstimulation SyndromeFAERS: 2SIDER
US FAERS
25Progesterone decreasedFAERS: 2US FAERS
26SwellingFAERS: 2SIDER
US FAERS
27VomitingFAERS: 2US FAERS
28Breast discomfortFAERS: 1US FAERS
29Device malfunctionFAERS: 1US FAERS
30Diabetes InsipidusFAERS: 1US FAERS
31Drug administration errorFAERS: 1US FAERS
32DysacusisFAERS: 1US FAERS
33HyperacusisFAERS: 1US FAERS
34HypotensionFAERS: 1SIDER
US FAERS
35Incorrect dose administered by deviceFAERS: 1US FAERS
36Infusion site erythemaFAERS: 1US FAERS
37Injection site irritationFAERS: 1US FAERS
38Injection site massFAERS: 1US FAERS
39Injection site painFAERS: 1US FAERS
40Injection site vesiclesFAERS: 1US FAERS
41Limb injuryFAERS: 1US FAERS
42MetrorrhagiaFAERS: 1US FAERS
43Myasthenia GravisFAERS: 1US FAERS
44Rash erythematousFAERS: 1US FAERS
45Respiratory distressFAERS: 1US FAERS
46ShockFAERS: 1US FAERS
47Skin reactionFAERS: 1US FAERS
48SyncopeFAERS: 1US FAERS
49Syringe issueFAERS: 1US FAERS
50TremorFAERS: 1US FAERS
51VIIth nerve paralysisFAERS: 1US FAERS
52Anaphylactic shockSIDER
53Anaphylactoid ReactionSIDER
54AnencephalySIDER
55DermatitisSIDER
56Diaphragmatic HerniaSIDER
57FertilizationSIDER
58GlaucomaSIDER
59Injection Site ReactionSIDER
60Local reactionSIDER
61Multiple Myeloma21062912CTD
62NevusSIDER
63Product quality issueCanada Vigilance: 1Canada Vigilance
64RednessSIDER
65StillbirthSIDER
66Trisomy 21SIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.